AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys
Phase 2 Weight Loss Results by Dose The dose-response relationship was clear: higher doses produced progressively greater weight loss
Does my insurance cover the recommended medication, and are there more affordable alternatives if coverage is an issue
Our findings suggest that tirzepatide, through its dual GIP/GLP-1 action, may be superior as a non-IOPlowering adjunct or even as a primary preventive agent in glaucoma management among patients with diabetes, the researchers wrote in their paper
Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, Charytan DM, Hadjadj S, Gillard P, Gorriz JL, Idorn T, Ji L, Mahaffey KW, Perkovic V, Rasmussen S, Schmieder RE, Pratley RE, Tuttle KR
Anyone familiar with how peptides work at the receptor level understands that GLP-1 activation creates systemic metabolic changes, not just appetite suppression
